Gerd Auffarth - Mar 7, 2024 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Director
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Mar 7, 2024
Transactions value $
$0
Form type
4
Date filed
3/8/2024, 04:14 PM
Previous filing
Oct 5, 2023
Next filing
Oct 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +94.4K $0.00 94.4K Mar 7, 2024 Common Stock 94.4K $0.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.